4D Molecular Therapeutics (FDMT) Corporate presentation summary

Platform and pipeline

• AAV evolution platform generates ~1 billion synthetic capsid sequences, then selects vectors for targeted tissue delivery and desired profiles such as dose, route, and antibody resistance.

• Pipeline includes 4D-150 for wet AMD and DME, 4D-175 for geographic atrophy, and aerosolized lung programs 4D-710 for cystic fibrosis and 4D-725 for lung disease.

4D-150 opportunity and wet AMD program

• Target profile is a single, in-office intravitreal injection enabling durable aflibercept expression as a backbone therapy for continuous disease control.

• Wet AMD and DME represented a combined ~$14B global branded retinal anti-VEGF market in 2025E; wet AMD prevalence was ~5M and DME prevalence ~4M across the U.S., Europe, and Japan.

• PRISM through two years showed supplemental injections down 79% in severe, recalcitrant patients (20.4 projected prior-period injections vs. 4.3 post-treatment), 78% in broad disease (12.0 vs. 2.7), and 87% in recently diagnosed patients (12.0 vs. 1.6).

• PRISM reported stable vision and retinal anatomy through two years in broad and recently diagnosed groups, and visual acuity and anatomy comparable to Q8W aflibercept in severe, recalcitrant patients.

• 4FRONT-1 and 4FRONT-2 enrollment was complete; topline data were expected in Q2 2027 and H2 2027, respectively.

DME program

• SPECTRA Part I at the Phase 3 dose showed stable vision and anatomy through two years; no intraocular inflammation or ocular serious adverse events were reported across 22 participants.

• SPECTRA showed a 61% reduction in supplemental injections versus projected aflibercept dosing; applying planned 4SIGHT criteria estimated a 75% reduction, with actual 4SIGHT results subject to variation.

• 4SIGHT enrolled its first patients in September 2026; the global Phase 3 trial planned 514 treatment-naïve participants and a Week 52 BCVA noninferiority comparison with aflibercept after five loading doses.

• Regulatory alignment supports potential filing with one DME Phase 3 trial combined with 4FRONT wet AMD data.